Antitumor antibodies, proteins, and uses thereof
AssigneeUniversity of Massachusetts
InventorsKenneth L. ROCK, Dancella FERNANDES
Life of this patent
Estimating the term…
Abstract
Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.
Claims20
A method for inhibiting tumor cell proliferation, comprising contacting a tumor cell with an effective amount of an isolated antibody, or antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of:
- (i) monoclonal antibody DMF10.62.3 produced by hybridoma cell line ATCC No. PTA-377;
- (ii) a chimeric version of antibody DMF10.62.3 comprising the light and heavy chain variable regions of monoclonal antibody DMF10.62.3 and human light and heavy chain constant regions, wherein said chimeric version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds;
- and
- (iii) a humanized version of antibody DMF10.62.3 comprising the complementarity determining regions (CDRs) of monoclonal antibody DMF10.62.3, wherein said humanized version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds such that tumor cell proliferation is inhibited.
A method of selectively delivering a moiety to a tumor cell in a subject, the method comprising administering to the mammal an isolated antibody, or antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of:
- (i) monoclonal antibody DMF10.62.3 produced by hybridoma cell line ATCC No. PTA-377;
- (ii) a chimeric version of antibody DMF10.62.3 comprising the light and heavy chain variable regions of monoclonal antibody DMF10.62.3 and human light and heavy chain constant regions, wherein said chimeric version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds;
- and
- (iii) a humanized version of antibody DMF10.62.3 comprising the complementarity determining regions (CDRs) of monoclonal antibody DMF10.62.3, wherein said humanized version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds,
- wherein the antibody is conjugated to a moiety selected from the group consisting of a radioactive molecule, a radionuclide, a sensitizer molecule, an imaging reagent, a radioisotope, a toxin, a cytotoxin, an anti-tumor agent, a chemotherapeutic agent, a modulator of the immune system, a cytokine and a reporter group;
- and allowing sufficient time for the complex to bind to the tumor cell, such that the moiety is selectively delivered to the tumor cell in the mammal.
A method for detecting a tumor cell in a subject, the method comprising contacting a cell in a subject with an isolated antibody, or antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of:
- (i) monoclonal antibody DMF10.62.3 produced by hybridoma cell line ATCC No. PTA-377;
- (ii) a chimeric version of antibody DMF10.62.3 comprising the light and heavy chain variable regions of monoclonal antibody DMF10.62.3 and human light and heavy chain constant regions, wherein said chimeric version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds;
- and
- (iii) a humanized version of antibody DMF10.62.3 comprising the complementarity determining regions (CDRs) of monoclonal antibody DMF10.62.3, wherein said humanized version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds, under conditions that enable specific binding;
- and detecting any specific binding of the antibody to the cell, wherein binding indicates the presence of a tumor cell in the subject.
A method for detecting a tumor cell in a subject, the method comprising contacting a cell removed from the subject with an isolated antibody, or antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of:
- (i) monoclonal antibody DMF10.62.3 produced by hybridoma cell line ATCC No. PTA-377;
- (ii) a chimeric version of antibody DMF10.62.3 comprising the light and heavy chain variable regions of monoclonal antibody DMF10.62.3 and human light and heavy chain constant regions, wherein said chimeric version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds;
- and
- (iii) a humanized version of antibody DMF10.62.3 comprising the complementarity determining regions (CDRs) of monoclonal antibody DMF10.62.3, wherein said humanized version specifically binds to the antigen to which monoclonal antibody DMF10.62.3 binds,
- under conditions that enable specific binding;
- and detecting any specific binding of the antibody to the cell, wherein binding indicates the presence of a tumor cell in the subject.
Dependencies are inferred from the claim text.